Emerging Data on IMiDs in the Treatment of Myelodysplastic Syndromes (MDS)
- 31 August 2005
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 32, 31-35
- https://doi.org/10.1053/j.seminoncol.2005.06.020
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Novel therapies for myelodysplastic syndromesCancer, 2004
- The evolution of thalidomide and its IMiD derivatives as anticancer agentsNature Reviews Cancer, 2004
- Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia, 2004
- Myelodysplastic syndromesThe Hematology Journal, 2004
- Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivoLeukemia, 2003
- Thalidomide for the treatment of patients with myelodysplastic syndromesLeukemia, 2002
- Proteolytic remodeling of extracellular matrixCurrent Opinion in Cell Biology, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982